Lexicon Pharmaceuticals, Inc. Q2 FY2026 earnings call

• Pipeline & Clinical Development Progress

  • The Sonata HCM Phase III trial evaluating sotagliflozin (soda) for symptomatic hypertrophic cardiomyopathy (HCM) has completed enrollment, with significant over-enrollment that improves study power. The trial includes a large majority of non-obstructive HCM (NHCM) patients (a group with limited approved treatment options) and a meaningful cohort of obstructive HCM (OHCM) patients, allowing assessment across the full HCM spectrum.
  • Top-line results from the Sonata HCM trial are expected in Q1 2027. The primary efficacy endpoint is change from baseline to week 26 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) for the overall trial population. Patients on stable guideline-directed HCM therapy, including approved cardiac myosin inhibitors (CMIs), were permitted to enroll for a pragmatic, real-world relevant study design.
  • For Zynquista (sotagliflozin) in type 1 diabetes, the Steno 1 investigator-initiated trial is on track to meet the FDA-required patient years of sodagliflozin exposure by the end of August 2026. The NDA resubmission is currently targeted for the end of October 2026.
  • LX-9851, a first-in-class ACSL-5 inhibitor for metabolic disease, is in Phase I development by licensee Novo Nordisk, and the collaboration is progressing well.

• Mechanism of Action Rationale for Sota in HCM

  • Sota is a unique dual SGLT1/SGLT2 inhibitor that directly targets the underlying diastolic dysfunction that characterizes both NHCM and OHCM. SGLT1 inhibition improves cardiac cell function via enhanced calcium flux, better energy utilization, reduced inflammation and fibrosis, and reduced epicardial fat, while SGLT2 inhibition benefits cardiorenal function, making it the only therapy that addresses HCM both inside and outside the heart.

• Financial and Balance Sheet Updates

  • Q2 2026 R&D expenses were $17.4 million (up from $15.7 million in Q2 2025), driven by higher external costs for the Sonata HCM trial. SG&A expenses were $9.8 million (up from $9.4 million in Q2 2025).
  • Q2 2026 net loss was $31.8 million ($0.07 per share), which includes a $4.3 million loss on early debt extinguishment from repaying the Oxford Finance term loan. This compares to net income of $3.3 million ($0.01 per share) in Q2 2025.
  • As of June 30, 2026, the company held $190.6 million in cash, cash equivalents, and short-term investments, up from $125.2 million at December 31, 2025.
  • In May 2026, Lexicon closed a new $100 million debt facility with Hercules Capital: an initial $55 million tranche was drawn to repay the prior Oxford Finance facility, a $20 million second tranche is available upon meeting clinical/regulatory/financial milestones, and a $25 million third tranche is available subject to Hercules consent. The facility includes an initial 18-month interest-only period, with two potential 6-month extensions.
  • The company has begun targeted pre-commercial investments in medical education, marketing preparation, and market access for late-stage assets, which are included in existing 2026 expense guidance.

• Corporate Strategy

  • The company is executing its "Lead to Succeed" strategy, focused on prioritizing high-impact opportunities with the highest probability of success. Management expects the next 12 months to be a transformative period for Lexicon, with key late-stage milestones for sotagliflozin that could expand the product's reach and patient impact.

Lexicon only reports total company-level financial results in this call, with no breakdown of separate product segment performance. For the quarter ended June 30, 2026, total revenue was $0.7 million, all from net sales of MPEFA. This compares to $28.9 million in total revenue in Q2 2025, which included $27.5 million in licensing revenue from the Novo Nordisk agreement plus net sales of Impefa. No absolute or percentage revenue contributions for individual product segments are provided.

• Total 2026 operating expense guidance is maintained at $100 million to $110 million, with R&D expenses expected to fall between $63 million and $68 million, and SG&A expenses between $37 million and $42 million. Pre-commercial investments for late-stage assets are already included in these estimates.

• The NDA resubmission for Zynquista in type 1 diabetes is dependent on the Steno Group, an investigator-initiated trial that was not originally designed for regulatory purposes, leading to delays in data formatting and collection. There is uncertainty around whether the final submitted data will meet FDA requirements for approval.
  • Positive topline results for the Sonata HCM trial are not guaranteed, and there is risk that the trial will not meet its primary endpoint, or that results will not be statistically or clinically meaningful in one or both HCM subtypes.
  • Access to future tranches of the Hercules Capital debt facility is subject to meeting clinical, regulatory, and financial milestones, or (for the third tranche) Hercules Capital consent, so there is no guarantee the full $100 million facility will be available to the company.

Q: How should we interpret the trial's NHCM-majority patient mix for commercial and regulatory value if the overall population is positive, and is directionality across both subtypes more important than magnitude in each group? / A: The trial was designed to be pragmatic, reflecting the current HCM patient population where NHCM has no approved treatments, while OHCM already has surgical and medical options. The trial is powered on the overall mixed population per FDA agreement, and over-enrollment increases confidence in the primary endpoint. The OHCM cohort is large enough to yield meaningful results for both subtypes, and the company sees commercial opportunity across both groups: soda can be used alone or in combination with existing CMIs, filling an unmet need in NHCM and helping symptomatic patients even in OHCM with existing treatments.

Q: Why has the Zynquista NDA resubmission been pushed to late October 2026 from the prior mid-2026 expectation, and what is the expected approval timeline? / A: Steno 1 is an investigator-initiated trial never designed for regulatory use, so formatting and aggregating the required data to meet FDA specifications has taken longer than initially anticipated. DKA rates in the soda treatment group are similar to standard of care and well below prior inTandem trial rates, which meets FDA requirements. If submitted in late October 2026, a 6-month Class 2 review would result in a decision in Q2 2027. Because the FDA has already reviewed much of the existing data for sodagliflozin, the company will proactively work with the FDA to explore a faster review than the statutory timeline.

Q: What proportion of Sonata trial patients are on CMIs, how might that impact results and prescribing, and what is soda's positioning relative to upcoming competing HCM programs? / A: The company will not release baseline patient characteristics, including CMI use and OHCM/NHCM proportions, until a future medical meeting. A fair number of patients are on CMIs, with enrollment across 20 countries (US is the largest single contributor but not a majority), and all patients on stable CMI doses were permitted to enroll. Soda's mechanism is complementary to existing and upcoming HCM therapies, so it can be prescribed as a standalone first-line treatment or in combination. As a once-daily oral medicine with a well-established safety and tolerability profile, it is well-positioned for broad early use by prescribers, with CMIs added later if patients remain symptomatic.

Q: What flexibility does the company have to adjust the statistical analysis plan if only one HCM subtype shows a positive effect, and what work has been done to prepare the Steno 1 data for NDA submission? / A: The primary endpoint (overall population KCCQ-CSS at week 26) will not change, aligned with FDA guidance and external advice. There may be minor adjustments to the hierarchy of secondary endpoints based on market developments before database lock. For Steno 1, the company has had extensive ongoing interaction with the study team, receiving monthly updates on exposure and DKA events, collecting translated narratives for all DKA cases, verifying that the study data can be formatted to meet FDA requirements, and confirming all required variables are collected properly. Existing large clinical trial data for soda plus the similar DKA rates to standard of care seen in Steno provide compelling support for the NDA.